Gene · 1066
Papers3,256
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,256
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanistic insights from a pilot exploratory study of the dynamic proteomic changes during plasma exchange in patients with acute liver failure. | Transfus Apher Sci | 2025 | 39566347 | PubTator, text mining | PubMed |
| Integrated analysis of ncRNA in hepatocellular carcinoma with CTNNB1 mutations reveals miR-205-5p and miR-3940-3p Axes. | Dig Liver Dis | 2025 | 38918127 | PubTator, text mining | PubMed |
| UGT2B15 single nucleotide polymorphism reduces dabigatran acylglucuronide formation in humans. | Front Pharmacol | 2024 | 39850575 | PubTator, text mining | PubMed |
| RNA Metabolism and the Role of Small RNAs in Regulating Multiple Aspects of RNA Metabolism. | Noncoding RNA | 2024 | 39846679 | PubTator, text mining | PubMed |
| CYP2C19 and CES1 gene variants affecting clopidogrel metabolism in a South Asian population from Sri Lanka. | Pharmacogenomics | 2024 | 39809701 | PubTator, text mining | PubMed |
| New High-Affinity Peptide Ligands for Kv1.2 Channel: Selective Blockers and Fluorescent Probes. | Cells | 2024 | 39768187 | PubTator, text mining | PubMed |
| Correction: Nicotine-induced CHRNA5 activation modulates CES1 expression, impacting head and neck squamous cell carcinoma recurrence and metastasis via MEK/ERK pathway. | Cell Death Dis | 2024 | 39706839 | PubTator, text mining | PubMed |
| Effective, but Safe? Physiologically Based Pharmacokinetic (PBPK)-Modeling-Based Dosing Study of Molnupiravir for Risk Assessment in Pediatric Subpopulations. | ACS Pharmacol Transl Sci | 2024 | 39698289 | PubTator, text mining | PubMed |
| Pharmacogenetics of dabigatran and apixaban in association with gastrointestinal bleeding. | Neuro Endocrinol Lett | 2024 | 39688660 | PubTator, text mining | PubMed |
| A novel necroptosis-related genes signature to predict prognosis and treatment response in bladder cancer. | Front Mol Biosci | 2024 | 39655212 | PubTator, text mining | PubMed |
| Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of dabigatran. | Front Pharmacol | 2024 | 39619611 | PubTator, text mining | PubMed |
| Randomized evaluation of the loss-of-function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics. | Clin Transl Sci | 2024 | 39576732 | PubTator, text mining | PubMed |
| CES1 is associated with cisplatin resistance and poor prognosis of head and neck squamous cell carcinoma. | Oncol Res | 2024 | 39574476 | PubTator, text mining | PubMed |
| ProBID-Net: a deep learning model for protein-protein binding interface design. | Chem Sci | 2024 | 39568891 | PubTator, text mining | PubMed |
Novel Ratiometric Surface-Enhanced Raman Scattering (SERS) Biosensor for Ultrasensitive Quantitative Monitoring of Human Carboxylesterase-1 in Hepatocellular Carcinoma Cells Using Ag-Au Nanoflowers as SERS Substrate. | Anal Chem | 2024 | 39498661 | PubTator, text mining | PubMed |
| Nicotine-induced CHRNA5 activation modulates CES1 expression, impacting head and neck squamous cell carcinoma recurrence and metastasis via MEK/ERK pathway. | Cell Death Dis | 2024 | 39472448 | PubTator, text mining | PubMed |
| Abnormally high plasma concentrations of M-4, the active metabolite of edoxaban, at the onset of acute kidney injury in a patient receiving rifampin and clarithromycin: a case report. | J Pharm Health Care Sci | 2024 | 39468637 | PubTator, text mining | PubMed |
| Circulating Factors as Potential Biomarkers of Cardiovascular Damage Progression Associated with Type 2 Diabetes. | Proteomes | 2024 | 39449501 | PubTator, text mining | PubMed |
| sesA: A Program for the Analytic Computation of Solvent-Excluded Surface Areas. | ChemistryOpen | 2024 | 39439129 | PubTator, text mining | PubMed |
| Proteomic analysis of plasma exosomes in patients with metastatic colorectal cancer. | Clin Proteomics | 2024 | 39385083 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1066/papers?page=9